These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 24718924)

  • 1. The tumor suppressor PTEN interacts with p53 in hereditary cancer (Review).
    Nakanishi A; Kitagishi Y; Ogura Y; Matsuda S
    Int J Oncol; 2014 Jun; 44(6):1813-9. PubMed ID: 24718924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.
    Blanco A; Graña B; Fachal L; Santamariña M; Cameselle-Teijeiro J; Ruíz-Ponte C; Carracedo A; Vega A
    Clin Genet; 2010 Feb; 77(2):193-6. PubMed ID: 19930417
    [No Abstract]   [Full Text] [Related]  

  • 3. PTEN autoregulates its expression by stabilization of p53 in a phosphatase-independent manner.
    Tang Y; Eng C
    Cancer Res; 2006 Jan; 66(2):736-42. PubMed ID: 16424003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome.
    Bennett KL; Mester J; Eng C
    JAMA; 2010 Dec; 304(24):2724-31. PubMed ID: 21177507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53.
    He X; Ni Y; Wang Y; Romigh T; Eng C
    Hum Mol Genet; 2011 Jan; 20(1):80-9. PubMed ID: 20926450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esophageal cancer in a family with hamartomatous tumors and germline PTEN frameshift and SMAD7 missense mutations.
    Sherman SK; Maxwell JE; Qian Q; Bellizzi AM; Braun TA; Iannettoni MD; Darbro BW; Howe JR
    Cancer Genet; 2015; 208(1-2):41-6. PubMed ID: 25554686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53 mutation "gradient effect" and its clinical implications.
    Zambetti GP
    J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN, more than the AKT pathway.
    Blanco-Aparicio C; Renner O; Leal JF; Carnero A
    Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
    Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
    Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Familial breast cancer, ovarian cancer].
    Inoue M
    Nihon Rinsho; 2006 Jun; Suppl 2():366-70. PubMed ID: 16817423
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain.
    Gu J; Kawai H; Wiederschain D; Yuan ZM
    Cancer Res; 2001 Feb; 61(4):1741-6. PubMed ID: 11245491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shaping genetic alterations in human cancer: the p53 mutation paradigm.
    Soussi T; Wiman KG
    Cancer Cell; 2007 Oct; 12(4):303-12. PubMed ID: 17936556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome.
    Debelenko LV; Perez-Atayde AR; Dubois SG; Grier HE; Pai SY; Shamberger RC; Kozakewich HP
    Pediatr Dev Pathol; 2010; 13(3):218-24. PubMed ID: 20028212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members.
    Lomax ME; Barnes DM; Hupp TR; Picksley SM; Camplejohn RS
    Oncogene; 1998 Aug; 17(5):643-9. PubMed ID: 9704930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational advances regarding hereditary breast cancer syndromes.
    Gage M; Wattendorf D; Henry LR
    J Surg Oncol; 2012 Apr; 105(5):444-51. PubMed ID: 22441895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer.
    Agrawal S; Eng C
    Hum Mol Genet; 2006 Mar; 15(5):777-87. PubMed ID: 16436456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression--transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway.
    Choi HJ; Chung TW; Kang SK; Lee YC; Ko JH; Kim JG; Kim CH
    Glycobiology; 2006 Jul; 16(7):573-83. PubMed ID: 16574813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.
    Rodríguez-Escudero I; Oliver MD; Andrés-Pons A; Molina M; Cid VJ; Pulido R
    Hum Mol Genet; 2011 Nov; 20(21):4132-42. PubMed ID: 21828076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing.
    Brown LT; Sexsmith E; Malkin D
    Cancer Genet Cytogenet; 2000 Nov; 123(1):65-8. PubMed ID: 11120338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel mutation of the PTEN gene in a Japanese patient with Cowden syndrome and bilateral breast cancer.
    Tate G; Suzuki T; Endo Y; Mitsuya T
    Cancer Genet Cytogenet; 2008 Jul; 184(1):67-71. PubMed ID: 18558293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.